Japanese drug maker
In the clinical trial, the drug curbed progress of symptoms such as worsening memory and impairment in judgment by 27 percent compared with a placebo,
The trial was conducted on about 1,800 patients with early symptoms in
The announcement comes after a panel at
Lecanemab removes a type of protein called amyloid beta, which accumulates inside the brain and destroys nerve cells, according to
==Kyodo
© Kyodo News International, Inc., source